Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has made a 81.49% comeback from a 12-month low price of $0.47. It was seen 4.66% higher, changing the price to $0.85, when the closing bell rang on 3/13/2019. At a recent session, the prices were hovering between $0.8101 and $0.87. This company shares are 782.35% off its target price of $7.5 and the current market capitalization stands at $5.2M. The recent change has given its price a 23.88% lead over SMA 50 and -78.68% deficit over its 52-week high. The stock witnessed 49.36% gains, 11.5% gains and -50.98% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found RTTR’s volatility during a week at 13.91% and during a month it has been found around 16.23%.Ritter Pharmaceuticals, Inc. (RTTR) Top Holders
Institutional investors currently hold around $1 million or 24.3% in RTTR stock. Look at its top three institutional owners: Sabby Management, Llc owns $280 thousand in Ritter Pharmaceuticals, Inc., which represents roughly 5.38% of the company’s market cap and approximately 28% of the institutional ownership. Similar statistics are true for the second largest owner, Baker Bros. Advisors Lp, which owns 279,999 shares of the stock are valued at $228 thousand. The third largest holder is Vanguard Group Inc, which currently holds $46 thousand worth of this stock and that ownership represents nearly 0.88% of its market capitalization.
At the end of December reporting period, 3 institutional holders increased their position in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by some 244,357 shares, 9 decreased positions by 179,741 and 5 held positions by 360,435. That puts total institutional holdings at 784,533 shares, according to SEC filings. The stock grabbed 1 new institutional investments totaling 31 shares while 6 institutional investors sold out their entire positions totaling 46,759 shares.Ritter Pharmaceuticals, Inc. (RTTR) Analyst Guide
Several analysts have released their opinion on Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].